On March 16, 2026, Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $15.1 million for the fourth quarter, a slight improvement from a net loss of $16.0 million in the same period of 2024. For the full year, Black Diamond posted a net income of $22.4 million, a significant turnaround from a net loss of $69.7 million in 2024. The company ended 2025 with approximately $128.7 million in cash, cash equivalents, and investments, which is expected to fund operations into the second half of 2028.

In terms of operational updates, Black Diamond provided a clinical update on its lead candidate, silevertinib, which is being developed for the treatment of patients with non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The company is on track to present updated results from the Phase 2 trial of silevertinib in NSCLC patients in the second quarter of 2026, including preliminary data on duration of response (DOR) and progression-free survival (PFS).

Additionally, Black Diamond is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR-altered GBM in the same timeframe. The company’s focus on advancing silevertinib reflects its commitment to addressing the unmet medical needs in oncology, particularly for patients with EGFR mutations.

The financial results and clinical updates indicate a positive trajectory for Black Diamond Therapeutics, suggesting that the company is making significant strides in both its financial health and its clinical development pipeline. Investors and stakeholders will be keenly watching the upcoming clinical presentations and trials as they could have a substantial impact on the company's future performance and stock price.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.